Martha L Arellano MD
Hematologic Oncology
Professor, Fellowship Program Director, Hematology and Medical Oncology, Winship Cancer Institute of Emory University
Join to View Full Profile
1365 Clifton Rd NEAtlanta, GA 30322
Phone+1 404-778-1900
Fax+1 404-778-3459
Dr. Arellano is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Emory University School of MedicineFellowship, Hematology and Medical Oncology, 2003 - 2006- Emory University School of MedicineResidency, Internal Medicine, 2000 - 2003
- Emory University School of MedicineClass of 2000
Certifications & Licensure
GA State Medical License 2003 - 2025
American Board of Internal Medicine Hematology
Clinical Trials
- Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2019 Mar 11
Roles: Contact
- Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia Start of enrollment: 2022 Jun 01
Roles: Contact
- Expanded Access Program for Revumenib
Roles: Contact
Publications & Presentations
PubMed
- Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial.Fieke W Hoff, Ying Huang, Rina Li Welkie, Ronan T Swords, Elie Traer
Blood Cancer Journal. 2025-04-03 - Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia.Vinod Pullarkat, Keith W Pratz, Hartmut Döhner, Christian Recher, Michael J Thirman
Blood Cancer Journal. 2025-03-28 - Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.Bijal D Shah, Ryan D Cassaday, Jae H Park, Roch Houot, Aaron C Logan
Leukemia. 2025-03-19
Journal Articles
- Venetoclax Combined with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid LeukemiaBrian A Jonas, Courtney D DiNardo, Olga Frankfurt, Daniel A Pollyea, Keith Pratz, Anthony Letai, Martha Arellano, Marina Konopleva, Hagop M Kantarjian, Blood
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AMLDaniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine
Abstracts/Posters
- Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based TherapiesClinically Relevant AbstractMartha L. Arellano, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Precision Medicine Treatment in Older AML: Results of Beat AML Master TrialClinically Relevant AbstractMartha L. Arellano, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart¬ Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) PatientsMartha L. Arellano, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
Relationships and Stem Cells Made the Difference for This Leukemia SurvivorSeptember 20th, 2021
OncLive® Presents State of the Science Summit™ on Hematologic MalignanciesOctober 31st, 2019
Winship Hematology and Medical Oncology Chief Fellow Receives Inaugural Khoury AwardJune 22nd, 2018- Join now to see all
Professional Memberships
- Member
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
